Bouza, EAlmirante, BGarcía Rodríguez, JGarnacho-Montero, JSalavert, MMuñoz, PSanguinetti, M2023-02-082023-02-082019-11-14http://hdl.handle.net/10668/14692The introduction of non-culture-based diagnostic techniques is revolutionizing the world of microbiological diagnosis and infection assessment. Fungi are no exception, and the introduction of biomarkers has opened up enormous expectations for better management of these entities. Biomarkers are diverse, their targets are also diverse and their evaluation has been done preferably in an individualized use and with deficient designs. Less is known about the value of the combined use of biomarkers and the impact of the negativity of two or more biomarkers on antifungal treatment decisions has been poorly studied. Given the paucity of prospective, randomized and definitive studies, we have convened experts from different fields, with an interest in invasive fungal infections, to answer some questions about the current relevant use of fungal biomarkers. This document summarizes the answers of these experts to the different questions.en1-3ß-D-GlucanAnti-MannanCAGTACandidemiaCritical CareGalactomannanIntensive CareInvasive candidiasisInvasive fungal infectionsMannanT2Candidaantifungal stewardshipfungal biomarkersinvasive aspergillosisAntibodies, FungalAspergillosisAspergillusBiomarkersBronchoalveolar LavageCandidaCandidemiaFalse Positive ReactionsFluorescent Antibody Technique, IndirectGalactoseGlucansHumansIntensive Care UnitsInvasive Fungal InfectionsMannansSensitivity and SpecificitySpainresearch article31729203open access10.37201/req/2260.20191988-9518PMC6987620https://seq.es/wp-content/uploads/2019/11/bouza14nov2019.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987620/pdf